Takara Nishiyama

Takara Nishiyama

Auto-generated profile, based on publicly available information

Takara Nishiyama

Interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SMSho Miyamoto
Sho Miyamoto
TNTakara Nishiyama
Takara Nishiyama
AUAkira Ueno
Akira Ueno
HPHyeongki Park
Hyeongki Park
TKTakayuki Kanno
Takayuki Kanno
TSTadaki Suzuki
Tadaki Suzuki
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.

11 March 2024 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
KKKosaku Kitagawa
Kosaku Kitagawa
KKKwang Su Kim
Kwang Su Kim
MIMasashi Iwamoto
Masashi Iwamoto
SHSanae Hayashi
Sanae Hayashi
HPHyeongki Park
Hyeongki Park
SIShingo Iwami
Shingo Iwami
Chronic infection with hepatitis B virus (HBV) is caused by the persistence of closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. Despite available therapeutic anti-HBV agents, eliminating the cccDNA remains challenging. Thus, quantifying and understanding the dynamics of cccDNA are essential for developing effective treatment strategies and new drugs. However, such study requires repeated liver biopsy to measure the intrahepatic cccDNA, which is basically not accepted because liver biopsy is potentially morbid and not common during hepatitis B treatment. We here aimed to develop a noninvasive method for quantifying cccDNA in the liver using surrogate markers in peripheral blood. We constructed a multiscale mathematical model that explicitly incorporates both intracellular and intercellular HBV infection processes. The model, based on age-structured partial differential equations, integrates experimental data from in vitro and in vivo investigations. By applying this model, we roughly predicted the amount and dynamics of intrahepatic cccDNA within a certain range using specific viral markers in serum samples, including HBV DNA, HBsAg, HBeAg, and HBcrAg. Our study represents a significant step towards advancing the understanding of chronic HBV infection. The noninvasive quantification of cccDNA using our proposed method holds promise for improving clinical analyses and treatment strategies. By comprehensively describing the interactions of all components involved in HBV infection, our multiscale mathematical model provides a valuable framework for further research and the development of targeted interventions.

25 November 2023 in Vaccine
Verified
Journal Article
Open access
TNTakara Nishiyama
Takara Nishiyama
YMYuichiro Miyamatsu
Yuichiro Miyamatsu
HPHyeongki Park
Hyeongki Park
NNNaotoshi Nakamura
Naotoshi Nakamura
RSRisa Yokokawa Shibata
Risa Yokokawa Shibata
YNYoji Nagasaki
Yoji Nagasaki
The 3-dose COVID-19 vaccine (booster vaccination) has been offered worldwide. As booster vaccinations continue, it is important to understand the antibody dynamics elicited by booster vaccination in order to evaluate and develop vaccination needs and strategies. Here, we investigated longitudinal data by monitoring IgG antibodies against the receptor binding domain (RBD) in health care workers. We extended our previously developed mathematical model to booster vaccines and successfully fitted antibody titers over time in the absence and presence of past SARS-CoV-2 infection. Quantitative analysis using our mathematical model indicated that anti-RBD IgG titers increase to a comparable extent after booster vaccination, regardless of the presence or absence of infection, but infection history extends the duration of antibody response by 1.28 times. Such a mathematical modeling approach can be used to inform future vaccination strategies on the basis of an individual's immune history. Our simple quantitative approach can be extended to any kind of vaccination and therefore can form a basis for policy decisions regarding the distribution of booster vaccines to strengthen immunity in future pandemics.

2 July 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
TNTakara Nishiyama
Takara Nishiyama
FMFuminari Miura
Fuminari Miura
YJYong Dam Jeong
Yong Dam Jeong
NNNaotoshi Nakamura
Naotoshi Nakamura
HPHyeongki Park
Hyeongki Park
PPPhillip R. Pittman
Phillip R. Pittman
Coinciding with the global outbreak of clade IIb mpox virus (MPXV), the Democratic Republic of the Congo (DRC) recently experienced a rapid surge in mpox cases with clade I MPXV. On 14 August 2024, the World Health Organization declared the continued cross-border spread of this clade in Africa a public health emergency of international concern (PHEIC). Clade I MPXV is known to be more fatal than clade IIb, but its clinical characteristics and prognosis differ between patients. Here, we used mathematical modeling to quantify temporal changes in total lesion counts during clade I MPXV infections, using data from a large cohort of patients with mpox in the DRC from 2007 to 2011. We further analyzed individuals’ clinical data to explore predictive biomarkers of high lesion counts. Our analysis indicates that patients with clade I mpox can be stratified into two groups according to lesion severity and that viral load in peripheral blood at symptom onset may serve as a predictor for this classification [area under the curve (AUC) = 0.70]. Our estimates also suggest substantial individual heterogeneity in the time period during which patients have lesions, ranging from 20 to 65 days. Understanding the severity and duration of lesions in different patients, as characterized by our approach, may contribute to more tailored treatment strategies and control measures in ongoing clade I mpox outbreaks.

29 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
TNTakara Nishiyama
Takara Nishiyama
FMFuminari Miura
Fuminari Miura
YJYong Dam Jeong
Yong Dam Jeong
NNNaotoshi Nakamura
Naotoshi Nakamura
HPHyeongki Park
Hyeongki Park
PPPhillip R. Pittman
Phillip R. Pittman
Coinciding with the global outbreak of clade IIb mpox virus (MPXV), the Democratic Republic of the Congo (DRC) recently experienced a rapid surge in mpox cases with clade I MPXV. Clade I MPXV is known to be more fatal, but its clinical characteristics and prognosis differ between patients. Here, we used mathematical modelling to quantify disease progression in a large cohort of mpox patients in the DRC from 2007-2011, particularly focusing on lesion transition dynamics. We further analyzed individuals’ clinical data to find predictive biomarkers of severity of symptoms. Our analysis shows that mpox patients can be stratified into three groups according to symptom severity, and that viral load at symptom onset may serve as a predictor to distinguish groups with the most severe or mild symptoms after progression. Understanding the severity and duration of symptoms in different patients, as characterized by our approach, allows treatment strategies to be improved and individual-specific control measures (e.g isolation strategies based on disease progression) to be developed.

4 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
KKKwang Su Kim
Kwang Su Kim
MIMasashi Iwamoto
Masashi Iwamoto
KKKosaku Kitagawa
Kosaku Kitagawa
SHSanae Hayashi
Sanae Hayashi
STSenko Tsukuda
Senko Tsukuda
YTYasuhito Tanaka
Yasuhito Tanaka
Evaluation of intrahepatic covalently closed circular DNA (cccDNA) is a key for searching an elimination of hepatitis B virus (HBV) infection. HBV RNA and HBV core-related antigen have been proposed as surrogate markers for evaluating cccDNA activity, although they do not necessarily estimate the amount of cccDNA. Here, we developed a novel multiscale mathematical model describing intra- and inter-cellular viral propagation, based on the experimental quantification data in both HBV-infected cell culture and humanized mouse models. We applied it to HBV-infected patients under treatment and developed a model which can predict intracellular HBV dynamics only by use of noninvasive extracellular surrogate biomarkers. Importantly, the model prediction of the amount of cccDNA in patients over time was confirmed to be well-correlated with the liver biopsy data. Thus, our noninvasive method enables to predict the amount of cccDNA in patients and contributes to determining the treatment endpoint required for elimination of intrahepatic cccDNA.